Pfizer Seeks FDA Approval For Adult COVID-19 Boosters

The video discusses a booster study showing 96% protection against symptomatic COVID-19, even with the Delta variant. The booster is a 30 microgram dose given six months after the initial two-shot series. There is high demand for boosters, especially after emergency approval for certain age groups. Moderna and Johnson & Johnson have authorized boosters, with specific eligibility criteria. The FDA and CDC have approved mixing and matching boosters, but none are authorized for those under 18. The approval process for boosters is faster due to it being a tweak to existing emergency authorizations.

What percentage of protection against symptomatic COVID-19 infection does the booster dose restore, according to the study?

• 85%

• 90%

• 96%

• 100%

How long after the primary series of two shots is the booster dose recommended?

• 12 months

• 6 months

• 9 months

• 3 months

Which age group is eligible for the Moderna booster?

• Only those 50 and older

• Anyone 12 and up

• Only those 65 and older

• Anyone 18 and up

What is the status of booster authorization for those under 18?

• Authorized only for high-risk individuals

• Fully authorized

• Partially authorized

• Not authorized

What is a significant change in the approval process for booster shots compared to previous vaccine authorizations?

• It involves more advisory committee meetings

• It requires more steps

• It is a completely new process

• It is a quicker, two-step process